[1] 国家市场监督管理总局.《药品注册管理办法》. 2020. [2] 国家药品监督管理局药品审评中心.《药品注册核查检验10启动工作程序(试行)》. 2021. [3] 国家药品监督管理局药品审评中心《. 关于发布《M4 模块一行政文件和药品信息》的通告》. 2020. [4] 国家药品监督管理局药品审评中心.《关于提交药品注册检查检验用申报资料光盘的通知》和常见问题及解答. 2019 [5] FDA. MAPP 5014.1 Rev.1. Understanding CDER’s RiskBased Site Selection Model. 2023. [6] FDA. Compliance Dashboards. Inspections. [7] EMA. Guidance for applicants/MAHs involved in GMP, GCPand GVP inspections coordinated by EMA. 2021. [8] EMA. Points to consider for assessors, inspectors and EMAinspection coordinators on the identification of triggers for theselection of applications for “routine” and/or “for cause”inspections, their investigation and scope of such inspections.2013. [9] EMA. Pre-authorisation guidance. Inspections. Informationrequired for identification of a need for pre-authorisation GCPinspections. 2022. [10] MHRA. Good Manufacturing Practice Pre-inspectionCompliance Report and Interim Compliance Report GuidelinesFor Completion and Submission. 2018.